In VivoRiding high on the wave of its dual GIP/GLP-1 agonist, tirzepatide, Eli Lilly awarded its CEO the highest total remuneration package of the top 12 big pharma companies in 2024. David Ricks’s total com
ScripIn a year that has so far been marked by major changes and upheaval at the US Food and Drug Administration, pharma companies are largely still on track with their expected 2025 approvals and launches.
ScripSummer is the time for sequels at the multiplex, and the biopharmaceutical sector offered a remake of its own as many of the datapoints for merger-and-acquisition activity during the second quarter ca
ScripModerna appears to have a pathway to approval for its investigational influenza/COVID-19 combination vaccine mRNA-1083 now that it reported positive Phase III efficacy data on June 30 for mRNA-1010, a